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Abstract 
Background:  Prognostic scores and models of illness severity are useful both clinically and for research. The aim of 
this study was to develop two prognostic models for the prediction of long‑term (6 months) and 28‑day mortality of 
postoperative critically ill patients with faecal peritonitis (FP).
Methods: Patients admitted to intensive care units with faecal peritonitis and recruited to the European GenOSept 
study were divided into a derivation and a geographical validation subset; patients subsequently recruited to the 
UK GAinS study were used for temporal validation. Using all 50 clinical and laboratory variables available on day 1 of 
critical care admission, Cox proportional hazards regression was fitted to select variables for inclusion in two prognos‑
tic models, using stepwise selection and nonparametric bootstrapping sampling techniques. Using Area under the 
receiver operating characteristic curve (AuROC) analysis, the performance of the models was compared to SOFA and 
APACHE II.
Results: Five variables (age, SOFA score, lowest temperature, highest heart rate, haematocrit) were entered into the 
prognostic models. The discriminatory performance of the 6‑month prognostic model yielded an AuROC 0.81 (95% 
CI 0.76–0.86), 0.73 (95% CI 0.69–0.78) and 0.76 (95% CI 0.69–0.83) for the derivation, geographic and temporal external 
validation cohorts, respectively. The 28‑day prognostic tool yielded an AuROC 0.82 (95% CI 0.77–0.88), 0.75 (95% CI 
0.69–0.80) and 0.79 (95% CI 0.71–0.87) for the same cohorts. These AuROCs appeared consistently superior to those 
obtained with the SOFA and APACHE II scores alone.
Conclusions: The two prognostic models developed for 6‑month and 28‑day mortality prediction in critically ill sep‑
tic patients with FP, in the postoperative phase, enhanced the day one SOFA score’s predictive utility by adding a few 
key variables: age, lowest recorded temperature, highest recorded heart rate and haematocrit. External validation of 
their predictive capability in larger cohorts is needed, before introduction of the proposed scores into clinical practice 
to inform decision making and the design of clinical trials.
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Background
Prognostic scores and models of illness severity are useful 
both clinically and for research. They support critical care 
physicians in decision making through more accurate 
prognostication; they describe and summarise case mix, 
and inform health economic evaluations of cost-effec-
tiveness. Many types of models exist, and their roles are 
not mutually exclusive, as their combined use may afford 
better prognostic reliability [1]. These tools are usually 
insufficiently accurate to be useful for predicting individ-
ual survival and are generally reserved for benchmarking 
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quality of care and for research studies [2–4], for exam-
ple when examining heterogeneity of treatment effect in 
clinical trials [5].
When considering prognostication in the context of 
the wide ranging spectrum of intra-abdominal infec-
tions, complexity is increased by the heterogeneity of 
aetiology, clinical manifestations and pathophysiological 
mechanisms. The International Sepsis Forum Consensus 
Conference on Definitions of Infection in the Intensive 
Care Unit describes intra-abdominal infections as a “very 
heterogeneous group of infectious processes that share 
an anatomical site between the diaphragm and the pel-
vis” [6]. The anatomical, clinical and pathophysiological 
heterogeneity of these infections, together with their var-
ied aetiology and prognosis, have given rise to a range of 
prognostic instruments tailored to specific populations.
Generic “peritonitis” prognostic tools (aimed at peri-
tonitis of any origin), such as the Mannheim Peritonitis 
Index (MPI) or the Peritonitis Index of Altona II (PIA II), 
rely on factors such as age, degree of organ failure, ori-
gin of sepsis and intra-operative findings to risk-stratify 
different types of peritonitis, but, given the consider-
able heterogeneity of intra-abdominal infections, these 
scoring systems may not be sufficiently specific in terms 
of aetiology [7, 8]. Other scoring systems have been 
devised to explicitly address the issue of prognostication 
in selected forms of peritonitis, such as the left colonic 
Peritonitis Severity Score (PSS), developed for patients 
with distal large bowel peritonitis of various origins [9]. 
The physiological and operative severity score for the 
enumeration of mortality and morbidity (POSSUM) is 
another risk adjustment model, developed in 1991 for 
use in surgical patients [10]. A modification of this prog-
nostic model, obtained by excluding some of the physi-
ological factors of the original POSSUM, was developed 
for use specifically in patients undergoing surgery for 
colorectal cancer (CR-POSSUM) [11]. Importantly, all of 
these scores incorporate intra-operative findings and are 
either designed to cater for, and include, the whole het-
erogeneous spectrum of peritoneal infections (such as 
the MPI and PIA II), or to focus on a very narrow subset 
of peritonitis, identified by location (left colonic, in the 
case of PSS) or aetiology (colorectal malignancy, as in 
CR-POSSUM).
To date no prognostic score has been developed for 
the critically ill patient with faecal peritonitis (FP) in 
the postoperative phase. We therefore aimed to specifi-
cally study critically ill patients suffering from FP, in the 
postoperative phase, and quantify their mortality risk at 
28 days and 6 months. International multicentre prospec-
tively collected patient datasets, such as The GenOSept 
and GAinS cohorts, provided an opportunity to develop 
and evaluate such prognostic systems.
Methods
Aim, design and setting
The Genetics of Sepsis and Septic Shock in Europe 
(GenOSept) and Genomic Advances in Sepsis (GAinS) 
are prospectively gathered cohorts of critically ill sep-
tic patients with FP recruited from multiple centres in 
Europe. They include data from patients with various 
degrees of illness severity, including potential risk modi-
fiers and confounding factors (such as comorbidities, 
indices of acute physiological derangement, organ sup-
port, radiological and laboratory findings, origin of FP) 
[12, 13]. These diagnostically homogeneous cohorts of FP 
patients, gathered primarily for the purposes of studying 
genetic epidemiology in sepsis, also provide high-qual-
ity data well suited to the development and testing of a 
prognostic model specific to this postoperative patient 
population.
The primary aim of this study was to develop and vali-
date a prognostic modelling tool able to stratify post-
surgical critically ill patients with FP, by quantifying 
their mortality risk in the short- (28 day) and long-term 
(6  month), independently from intra-operative surgi-
cal findings, using prospectively collected data from the 
GenOSept and GAinS cohorts.
Recruitment criteria
The same inclusion and exclusion criteria were used for 
both cohorts. Inclusion criteria: adult patients (>18 years) 
admitted to a High Dependency Unit (HDU) or Intensive 
Care Unit (ICU) with FP, defined as visible inflammation 
of the serosal membrane that lines the abdominal cavity, 
secondary to contamination by faeces, as diagnosed by the 
operating surgeon at laparotomy. All critically ill patients 
in this cohort, therefore, were recruited after the diagnosis 
was established during surgical source control. Exclusion 
criteria: peritonitis due to gastric or upper GI-tract per-
foration (e.g. gastric or duodenal ulcer perforation, small 
bowel perforation), patient or legal representative unwill-
ing or unable to give consent; patient pregnant; advanced 
directive to withhold or withdraw life-sustaining treat-
ment or admitted for palliative care only; patient already 
enrolled in an interventional research study of a novel/
unlicensed therapy (patients enrolled in interventional 
studies examining the clinical application or therapeutic 
effects of widely accepted, “standard” treatments, were 
not excluded); patient immunocompromised (known 
regular systemic corticosteroid therapy, exceeding 7 mg/
kg/day of hydrocortisone or equivalent, within 3 months 
of admission and prior to acute episode; known regular 
therapy with other immunosuppressive agents, e.g. aza-
thioprine; known to be HIV positive or have acquired 
immunodeficiency syndrome as defined by the Centre for 
Disease Control; neutrophil count less than 1000  mm−3 
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due to any cause, including metastatic disease and hae-
matological malignancies or chemotherapy, but excluding 
severe sepsis; organ or bone marrow transplant receiving 
immunosuppressive therapy).
The definition of sepsis was based on the International 
Consensus Criteria: “the clinical syndrome defined by the 
presence of both infection and a systemic inflammatory 
response” [14]. Patients were followed for up to 6 months 
from enrolment or until death.
Database and quality assurance
The case report form (CRF) was developed and tested 
by CH, CG, AG, JDC and Dr J. Millo, together with 
other members of the GenOSept Consortium. Vari-
ables recorded included demographic, clinical and out-
come data. A specific electronic case report form (eCRF) 
was developed by Lincoln, Paris, France, using software 
developed in collaboration with JDC. The database was 
password-protected, allowing investigators to enter data 
into the eCRF online, and included audit trail capability 
for data entry and subsequent modifications. To mini-
mise errors, logical range checks were in place so that the 
investigators would be alerted if an attempt was made to 
enter data values outside the expected ranges.
Quality assurance (QA) was performed by P.H., C.G., 
A.W., A.G. and C.H, who systematically reviewed all 
data. Data queries (DQs) were generated within the eCRF 
for missing or erroneous data and sent electronically to 
the relevant investigators for action, where necessary. Up 
to the end of January 2011, an estimated 3986 valid DQs 
had been generated, with a response rate by the investi-
gators of approximately 92%. Common reasons for DQs 
were missing information, particularly the Charlson 
Index, antimicrobial use, estimated day of onset of FP 
before ICU admission, information about circumstances 
of GCS assessment and outcome data.
All patients’ eCRFs were reviewed by experienced 
critical care physicians. Where the patient’s eligibility for 
inclusion in the relevant cohort was unclear, clarification 
was sought from the investigators. Regular QA reports 
were provided to the relevant Management Committee 
for review; the National Investigators were contacted 
regarding quality issues if necessary.
Statistical analyses
Prognostic model
In order to build the prognostic model, patients recruited 
up to January 2011 (included in the GenOSept cohort) 
were divided into two subsets of patients: one for deri-
vation and the other for external geographic validation. 
To limit the effect of potentially unmeasured and unac-
counted confounding factors, related to possible differ-
ences in national systems of healthcare provision among 
participating countries across Europe, these patients 
were divided into UK (derivation) and non-UK (geo-
graphic validation) sub-cohorts, with the aim of optimis-
ing homogeneity in the datasets and decreasing potential 
background noise. Subsequent patients recruited in the 
UK between January 2011 and March 2015 (included in 
the GAinS cohort) were included in the temporal valida-
tion cohort.
We evaluated all 50 clinical and laboratory variables 
available on admission to critical care (day 1) (for a full 
list, see Additional file  1). The primary outcome was 
6-month mortality risk with the secondary outcome 
being 28-day mortality risk. To select the variables to 
include in the model, Cox proportional hazards regres-
sion analysis for 6-month mortality was fitted, using step-
wise backwards selection, to determine the predictors to 
be included in the models from 50 bootstrapped samples 
derived from the derivation subset (nonparametric boot-
strap procedure). Increasing the number of bootstrap 
replications did not alter the model significantly. The p 
value cut-off used was 0.05. The same predictor variables 
were employed to construct a prognostic tool for the sec-
ondary outcome, 28-day mortality.
The procedure of bootstrapping is a re-sampling 
method which relies on random sampling with replace-
ment of the available observations. This procedure allows 
evaluation of the characteristics of an estimator (such as 
its variance) by measuring those properties when obtain-
ing multiple samples from the original dataset (and of 
size equal to the observed dataset) [15, 16].
A final Cox proportional hazards regression analysis 
for both 6-month and 28-day mortalities was fitted using 
the set of variables found to be significant in the majority 
of bootstrap replications.
We confirmed that the proportional hazards assump-
tion was met by drawing Kaplan–Meier Curves and 
Nelson Aalen plots for the covariates after categorisa-
tion. Predictors which satisfy the proportional hazard 
assumption show very similar curves, with the separation 
between them remaining proportional across analysis 
time [17]. We also tested the correctness of this assump-
tion testing on the basis of Schoenfeld residuals [18].
In order to assess for the presence of collinearity (which 
happens when two variables are almost perfect linear 
combinations of one another), we calculated the variance 
inflation factors (VIFs). It is generally accepted that vari-
ables with VIFs greater than 10 merit further investiga-
tion [19].
The two models obtained were evaluated using 
area under the receiver operating characteristic curve 
(AuROC) analysis, which plots sensitivity against 1-spec-
ificity to describe the accuracy of a diagnostic test [20, 21] 
and to compare the performance of different tests [22].
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Nonparametric bootstrapping and prognostic model 
derivation for 6‑month mortality
The bootstrapping procedure was performed using 
50 repetitions based on the UK derivation cohort. A 
final Cox proportional hazards regression analysis for 
6-month mortality was fitted using the set of variables 
found to be significant in the majority of bootstrap rep-
lications. Saturation was reached after 50 bootstrap 
replications, with additional replications not yielding sig-
nificantly different results.
A set of 5 variables assessed on day 1 met this criterion 
(age, SOFA score, lowest temperature, highest heart rate, 
haematocrit). The Cox proportional hazards model esti-
mates for those risk variables are presented in Table 1.
The same five variables were employed to formulate 
the 6-month mortality prognostic tool by entering the 
estimates obtained from the Cox proportional hazards 
model in the following equation:
where A =  age at admission to critical care, S =  SOFA 
score day 1, T  =  lowest recorded temperature (as °C) 
on day 1, HR  =  highest recorded heart rate on day 1, 
H = haematocrit (as percentage points) on day 1.
The model coefficients used for prediction of 6-month 
mortality were adjusted for the 28-day mortality out-
come. To achieve this, a separate Cox proportional 
FP score (6month) =
(
103
)
∗ exp ((0.0447387 ∗ A)
+(0.1812872 ∗ S)+ (−0.2767377 ∗ T )
+(0.0114629 ∗HR)+ (−0.0313029 ∗H))
hazards regression analysis was fitted for 28-day mortal-
ity, utilising the same set of five variables. The resulting 
model estimates are presented in Table 1. The estimates 
were utilised to construct the 28-day mortality prognos-
tic tool as described in the following equation:
While haematocrit and high heart rate did not offer inde-
pendent predictive power in the 28-day mortality model, 
they were useful in explaining variability when retained 
in the model.
Comparison of the prognostic models with preexisting scores
Comparison of the prognostic models with SOFA and 
APACHE II was performed graphically by drawing the 
superimposed ROC curves and testing the underlying 
AuROC obtained, taking into account that the data are 
correlated, using a nonparametric approach as suggested 
by DeLong et al. [23].
For all statistical analyses, Stata version 10.0 was used 
(StataCorp, Texas, USA; http://www.stata.com).
Results
Baseline and outcome data
The derivation cohort included 462 patients with FP 
recruited in the UK. Their median (inter-quartile range, 
IQR) age was 69.4 (58.6–77.2)  years. The geographic 
validation (non-UK) cohort included 515 FP patients 
recruited to the GenOSept study from the other Euro-
pean countries. Their median (IQR) age was 69.1 (58–
77)  years. The temporal validation cohort included 323 
FP patients recruited in the UK between January 2011 
and March 2015. Their median (IQR) age was 68.3 (57.6–
77.2)  years. For details of the recruiting centres, please 
see Additional file 1.
The baseline characteristics and the outcomes of 
the three cohorts are presented in Tables  2 and 3, 
respectively.
The age distribution was not significantly different 
across the cohorts, although the derivation cohort had 
a higher proportion of patients aged over 75. Males pre-
dominated in all cohorts. The racial distribution was 
more heterogeneous in the geographic validation cohort, 
while the derivation and the temporal validation cohorts 
were almost entirely Caucasian. Among the comorbidi-
ties diabetes, previous serious infections and other ill-
nesses were more prevalent in the geographic validation 
cohort, compared to the other cohorts. The underlying 
causes for FP varied across cohorts, with anastomotic 
breakdown being particularly common in the geographic 
FP score
(
28 day
)
=
(
104
)
∗ exp ((0.048728 ∗ A)
+(0.2005776 ∗ S)+ (−0.3591817 ∗ T )
+(0.0098462 ∗HR)+ (−0.0125259 ∗H))
Table 1 Variables found to  be significant in  the majority 
of bootstrap replications run on the UK derivation cohort 
for the two outcomes
HR hazard ratio; 95% CI 95% confidence interval, coeff coefficient, SOFA 
Sequential Organ Failure Assessment; the use of the square brackets [] indicates 
negative values
Variable HR HR 95% CI coeff coeff 95% CI p
6 month mortality
 Age 1.05 1.03–1.07 0.045 0.02–0.06 <0.001
 SOFA score 1.20 1.12–1.28 0.18 0.11–0.25 <0.001
 Low  
temperature
0.76 0.63–0.91 [−0.28] [−0.46]–[−0.09] 0.004
 High heart rate 1.01 1.01–1.02 0.01 0.01–0.02 0.007
 Haematocrit 0.97 0.94–0.99 [−0.031] [−0.059]–[−0.003] 0.028
28‑day mortality
 Age 1.05 1.03–1.08 0.049 0.03–0.07 <0.001
 SOFA score 1.22 1.12–1.33 0.2 0.11–0.29 <0.001
 Low  
temperature
0.70 0.55–0.88 [−0.36] [−0.59]–[−0.13] 0.002
 High heart rate 1.01 1–1.02 0.01 [−0.001]–0.2 0.07
 Haematocrit 0.99 0.95–1.02 [−0.013] [−0.047]–0.022 0.47
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Table 2 Patients’ baseline characteristics for the derivation, geographic and temporal external validation sub-cohorts
Cohort Derivation (UK until Jan 2011) Geographic validation (non-UK) Temporal validation (UK  
post-Jan 2011)
Total number of patients 462 515 323
Characteristics Median or n IQR or % Median or n IQR or % Median or n IQR or %
Age
Available data 462 100% 515 100% 323 100%
 18–34 11 2.4% 25 4.9% 11 3.4%
 35–44 15 3.3% 18 3.5% 16 5%
 45–54 54 11.7% 52 10.1% 38 11.8%
 55–64 93 20.1% 98 19% 73 22.6%
 65–74 113 24.5% 151 29.3% 88 27.2%
 75–84 149 32.3% 149 28.9% 75 23.2%
 85–95 27 5.8% 22 4.3% 22 6.8%
Gender
Available data 462 100% 515 100% 323 100%
 Male 236 51.1% 304 59% 171 52.9%
 Female 226 48.9% 211 41% 152 47.1%
Race
Available data 460 99.6% 510 99% 323 100%
 Caucasian 454 98.7% 502 98.4% 315 97.5%
 Asian 4 0.9% 7 1.4% 3 0.9%
 African 1 0.2% 1 0.2% 3 0.9%
 Mixed 1 0.2% 0 0% 2 0.6%
Medical comorbidities
Available data 462 100% 515 100% 323 100%
 Heart and vascular disease 187 40.6% 202 39.2% 117 36.2%
 Respiratory disease 111 24.1% 133 25.8% 97 30%
 Neurological disease 48 10.4% 57 11.1% 24 7.4%
 Severe renal disease 39 8.6% 21 4.3% 16 5%
 Gastrointestinal disease 98 21.3% 132 25.7% 76 23.5%
 Malignancy 135 29.3% 160 31.1% 84 26%
 Diabetes 61 13.2% 102 19.8% 44 13.6%
 Previous serious  infectiona 8 1.7% 25 4.9% 5 1.6%
 Other illness 130 28.2% 210 40.8% 83 25.7%
 Severe exercise restriction 3 0.7% 6 1.2% 1 0.3%
 Chronic dialysis 5 1.1% 8 1.6% 5 1.6%
 Chronic steroids  useb 2 0.4% 9 1.8% 5 1.6%
Cause of FP
Available data 461 99.8% 511 99.2% 323 100%
 Perforated diverticulum 137 29.7% 175 34.3% 89 27.6%
 Anastomotic breakdown 115 25% 187 36.6% 61 18.9%
 Malignancy 65 14.1% 64 12.5% 35 10.8%
 Trauma 22 4.8% 45 8.8% 16 5%
 Other 122 26.5% 40 7.8% 124 38.4%
Time to surgery (days) 1 1–3 1 1–3 1 1–3
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validation cohort. Baseline Sequential Organ Failure 
Assessment (SOFA) and Acute Physiology and Chronic 
Health Evaluation II (APACHE II) scores and prevalence 
of mechanical ventilation on day one were comparable 
across the cohorts. The occurrence of acute renal failure 
on day one was more frequent in the geographic valida-
tion cohort, with differences with the other cohorts (32.7, 
42.8 and 23.3% for the derivation, geographic and tem-
poral validation cohorts, respectively), accompanied by a 
difference in the utilisation of renal replacement therapy 
(21, 21.3 and 7.5% for the derivation, geographic and 
temporal validation cohorts, respectively) on day one. 
The geographic validation cohort was characterised by 
higher mortality rates (at all time points) and longer ICU 
stay, compared to the other two cohorts; this latter fea-
ture was also reflected, although to a lesser extent, in the 
length of hospital stay.
Performance of the prognostic tools
When evaluated using a receiver operating character-
istics (ROC) curve, the discriminatory performance of 
the 6-month prognostic model in the UK derivation sub-
cohort yielded an AuROC of 0.81 (95% CI 0.76–0.86) as 
indicated in Fig. 1a. At geographic validation in the non-
UK sub-cohort, the 6-month prognostic model produced 
an AuROC of 0.73 (95% CI 0.69–0.78; Fig. 1b). At tempo-
ral validation, the 6-month model yielded an AuROC of 
0.76 (95% CI 0.69–0.83; Fig. 1c).
The 28-day prognostic tool also performed similarly, 
yielding an AuROC 0.82 (95% CI 0.77–0.88; Fig. 2a) for 
the derivation UK sub-cohort. At geographic validation 
in the non-UK sub-cohort, the 28-day prognostic model 
produced an AuROC of 0.75 (95% CI 0.69–0.80; Fig. 2b). 
In the temporal validation cohort, the 28-day model 
yielded an AuROC of 0.79 (95% CI 0.71–0.87; Fig. 2c).
Table 2 continued
Characteristics Median or n IQR or % Median or n IQR or % Median or n IQR or %
Acute physiology
Available data 461 99.8% 513 99.6% 321 99.4%
 APACHE II score 15 12–20 17 13–22 16 12–21
 SOFA score 7 5–9 7 5–11 6 5–8
 Acute renal failure 129 32.7% 214 42.8% 70 21.8%
 Renal replacement therapy 81 21% 105 21.3% 26 8.1%
 Mechanical ventilation 346 75.1% 397 77.4% 228 71%
APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment
a Serious infection was defined as a serious, prolonged or recurrent infection
b Chronic steroid use was defined as taking corticosteroids below the immunosuppression dose (>7 mg/kg/days hydrocortisone), which would exclude patient from 
inclusion in the study
Table 3 Outcomes for the derivation, geographic and temporal external sub-cohorts
Cohort Derivation (UK until Jan 2011) Geographic validation (non-UK) Temporal validation (UK post-Jan 2011)
Total number of patients 462 515 323
Characteristics
Length of stay (days) Median IQR Median IQR Median IQR
Available data 462 100% 515 100% 322 99.7%
 ICU 7 4–14 14 7–29 6 3–11
 Hospital 26 14–47 30 17–54 29 18–47
Mortality n % n % n %
Available data 462 100 515 100 321 99.4
 6 month 124 26.8 185 35.9 64 19.9
 ICU 73 15.8 131 25.4 24 7.5
 Hospital 109 23.6 171 33.2 29 9.8
 28 day 79 17.1 171 33.2 40 12.4
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The 6-month FP prognostic score produced numeri-
cal values which can be stratified within 5 intervals 
(0–2; above 2–4; above 4–6; above 6–12; above 12) cor-
responding to five levels of 6-month mortality risk. The 
28-day mortality FP score produces values classified 
within 5 intervals, corresponding to different risk catego-
ries for the outcome (0–2; above 2–4; above 4–8; above 
8–16; above 16). The observed mortality rates corre-
sponding to each class of risk for the two scoring systems 
are presented in Table 4 for all three cohorts (Additional 
file  1: Figs. S1 and S2 display the corresponding histo-
grams of mortality). A 6-month FP score above 12 is con-
sistently associated with a greater than 50% mortality risk 
at 6 months across all cohorts. A 28-day FP score above 
16 is associated with a greater than 40% mortality risk for 
the 28-day outcome for the derivation and geographic 
validation cohorts, but not for the temporal validation 
cohort, in which the highest observed mortality risk was 
around 22%. 
The discriminatory capabilities of the FP prognostic tools 
versus the SOFA and APACHE II scores in the FP cohorts
To assess how the FP models compare, as prognostic 
tools, to the routinely used SOFA and APACHE II scores, 
we calculated AuROCs for these scoring systems, to pre-
dict 6-month and 28-day mortality, in order to compare 
each tool across all cohorts and for both outcomes. For 
6-month mortality, the SOFA score produced AuROCs 
of 0.73 (95% CI 0.68–0.78), 0.68 (95% CI 0.63–0.72) and 
0.62 (95% CI 0.54–0.7) in the derivation, geographic and 
temporal external validation cohorts, respectively, while 
the APACHE II score yielded AuROCs of 0.74 (95% CI 
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Fig. 1 Receiver operating characteristics (ROC) curve obtained when applying the 6‑month prognostic model to the derivation (a), geographic 
validation (b) and temporal validation sub‑cohorts (c) respectively; AuROC area under the receiver operating characteristic curve, CI confidence 
interval
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Fig. 2 Receiver operating characteristics (ROC) curve obtained when applying the 28 day prognostic model to the derivation (a), geographic vali‑
dation (b) and temporal validation sub‑cohorts (c) respectively; AuROC area under the receiver operating characteristic curve, CI confidence interval
Table 4 Observed 6-month and 28-day mortality rates for the derivation, geographic and temporal external validation 
sub-cohorts, stratified by FP score interval
Cohort Derivation (UK until Jan 2011) Geographic validation (non-UK) Temporal validation (UK post-Jan 2011)
FP score Deceased Deceased Deceased
6‑month mortality
 0–2 3 (3.7%) 14 (13.7%) 5 (6.3%)
 >2–4 11 (10.8%) 25 (22.5%) 7 (10.5%)
 >4–6 14 (20%) 29 (36.3%) 12 (26.1%)
 >6–12 29 (31.9%) 44 (40.7%) 15 (28.9%)
 >12 67 (57.3%) 73 (64%) 22 (59.5%)
28‑day mortality
 0–2 0 (0%) 10 (9.9%) 2 (2.7%)
 >2–4 8 (8.3%) 12 (12%) 3 (5.4%)
 >4–8 10 (9.5%) 17 (15.3%) 8 (11.1%)
 >8–16 14 (16.5%) 27 (26.2%) 12 (22.2%)
 >16 47 (45.6%) 42 (42%) 15 (22.4%)
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0.7–0.79), 0.71 (95% CI 0.66–0.75) and 0.69 (95% CI 
0.62–0.77) for those cohorts, respectively. For the 28-day 
mortality outcome, the SOFA score produced AuROCs 
of 0.76 (95% CI 0.7–0.82), 0.66 (95% CI 0.6–0.73) and 
0.67 (95% CI 0.58–0.77) in the derivation, geographic and 
temporal external validation cohorts, respectively, while 
the same AuROCs for the APACHE II score were 0.71 
(95% CI 0.64–0.77), 0.69 (95% CI 0.63–0.75) and 0.75 
(95% CI 0.67–0.83), respectively.
The AuROCs obtained using the FP scores were con-
sistently superior to those obtained with the SOFA score, 
with statistical significance across all cohorts (deriva-
tion, geographic and temporal external validation) and 
for both 6-month and 28-day mortality outcomes (Addi-
tional file 1: Figs. S3 and S4, respectively).
The AuROCs obtained using the FP scores were also 
superior to those derived using the APACHE II score 
for both outcomes, although statistical significance was 
not consistently achieved across all cohorts (Additional 
file 1: Figs. S5 and S6, for 6-month and 28-day mortality, 
respectively).
Discussion
Faecal peritonitis continues to be associated with a 
high mortality. Approximately one out of five critically 
unwell patients with FP in Europe will die in the inten-
sive care unit; this mortality rate increases to over 30% at 
6 months.
As we previously reported, and perhaps unexpectedly, 
the presence of co-morbidities, the time from presumed 
onset of symptoms to surgery, the underlying cause of FP 
and the degree of organ support needed in critical care 
did not appear to influence survival significantly in these 
postoperative critically ill patients [24, 25]. We are not 
aware of any prognostic tool designed to assess the risk of 
long-term mortality specifically in the critically ill post-
surgical FP patient. The risk prediction models described 
in our study aim to improve the SOFA score’s predictive 
power for mortality at 6 months and 28 days, by adding 
just a few key variables: age, lowest recorded tempera-
ture, highest recorded heart rate and haematocrit on 
admission to intensive care.
The 6-month mortality model demonstrates AuROCs 
of 0.81 (0.76–0.86), 0.73 (0.69–0.78) in the derivation 
and geographic validation cohorts, respectively, while the 
28-day prognostic tool yielded AuROCs of 0.82 (0.77–
0.88) and 0.75 (0.69–0.80) for the same cohorts. An area 
under the ROC curve over 0.8 is generally regarded as 
indicating a good discriminatory capacity [26]. In the 
temporal validation cohort, the 6-month and 28-day 
mortality models yielded AuROC of 0.76 (95% CI 0.69–
0.83) and 0.79 (0.71–0.87), respectively. The models, 
therefore, retained reasonable discriminatory capability, 
and systematically outperformed the other scoring sys-
tems tested (SOFA and APACHE II), in these cohorts.
This FP prognostic tool may, therefore, be useful to 
complement the currently used risk scores and bedside 
clinical assessment, enhancing the critical care clinician’s 
capacity to predict long-term outcome, thereby support-
ing the clinical decision making process in the postopera-
tive phase.
The prognostic models presented here have some 
strengths, particularly as they have been derived and 
internally validated using large, homogeneous and 
recently gathered cohorts of FP patients (hence reflecting 
current practices and therapies).
Biondo and colleagues have recently evaluated the per-
formance of the MPI as a predictor of immediate postop-
erative mortality, demonstrating an AuROC of 0.72 (95% 
CI 0.65–0.79), while, for the more specific left colonic 
Peritonitis Severity Score (PSS), the AuROC was 0.79 
(95% CI 0.72–0.85) for this outcome [27].
We have previously reported that factors such as age, 
acute renal dysfunction, hypothermia, lower haema-
tocrit and thrombocytopaenia are associated with an 
increased risk of death from FP [24, 25], and a number 
of other studies have evaluated the prognostic relevance 
of the individual components of our proposed prognostic 
models.
SOFA
The SOFA score was developed in a mixed (medical and 
surgical) ICU population [28] and has been subsequently 
externally validated in various populations [1], such 
as cardiac surgical patients [29] and critically ill burn 
patients [30].
While the SOFA score was originally developed for the 
purpose of describing the evolution of organ dysfunction, 
rather than for prognostic purposes, we previously found 
that both admission SOFA and trends in the global SOFA 
scores were closely associated with mortality [25]. Many 
studies have reported the use of the SOFA score both in 
isolation [31–35] and in combination with other variables 
[36, 37], for the purpose of outcome prediction. In our 
study, neither the SOFA nor the APACHE II scores, when 
used in isolation, performed as well as the tools devel-
oped here. Furthermore, day one SOFA performed par-
ticularly poorly in the temporal validation group, while 
the APACHE II risk model (which was developed for the 
purpose of outcome prediction) performed more consist-
ently across the three cohorts, both for the 6-month and 
the 28-day outcome. This finding suggests that the value 
of SOFA lies primarily in describing temporal changes in 
organ function. Nevertheless, a single SOFA score can be 
successfully integrated with other parameters, to provide 
a prognostic tool with improved accuracy [36, 37], as we 
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have done for day one SOFA in these analyses. While 
the confidence intervals for the AuROCs were relatively 
wide, when the FP models were compared to SOFA, sta-
tistically significant differences were found across all 
cohorts. This was not always the case for comparisons 
with APACHE II, further highlighting the superior prog-
nostic accuracy of this severity score compared to an iso-
lated, day one SOFA score.
Hypothermia
The adverse effect of hypothermia on the outcome of 
critically ill patients has been described by other authors, 
although data on the relevance of hypothermia to out-
comes remain conflicting [38, 39]. Laupland and co-
authors studied 10,962 medical, non-scheduled and 
scheduled surgical patients admitted to critical care with 
varying degrees of hypothermia and fever. Hypother-
mia was, after controlling for confounding factors, sig-
nificantly and independently associated with mortality 
in medical patients [38]. Tiruvoipati et al. reported data 
from 175 elderly ICU patients, identifying lower tem-
peratures and the Simplified Acute Physiology Score II 
(SAPS II) during the first day of ICU admission as being 
independently associated with higher hospital mortal-
ity [39, 40]. An association between severe hypothermia 
and the risk of ICU acquired infections has also been 
reported among medical patients [41].
Highest recorded heart rate
An increased heart rate is a physiological response to 
infection and sepsis, and part of the systemic inflamma-
tory response syndrome (SIRS). Sprung and colleagues 
found that the presence of SIRS predicts infection, sever-
ity of illness, organ failure and outcome, with the two 
most common SIRS criteria met during ICU stay being 
respiratory rate (82%) and heart rate (80%) [42]. Morelli 
and co-workers randomised a total of 154 septic shock 
patients to receive a continuous infusion of esmolol 
(targeting a heart rate of 80–94 bpm) or standard treat-
ment in an open label trial. The patients in the esmolol 
arm achieved lower heart rates, without an increase of 
adverse events. Interestingly, an improvement in survival 
and other secondary outcomes was also reported [43]. 
Others have found that a high daily mean heart rate was a 
significant predictor of ICU mortality [44].
Haematocrit
Anaemia in surgical patients undergoing both car-
diac and non-cardiac procedures has previously been 
reported to be associated with worse outcomes [45–49]. 
Beattie and co-workers performed a retrospective obser-
vational study of 7759 non-cardiac surgical patients to 
establish the relationship between preoperative anaemia 
and postoperative mortality and found that preoperative 
anaemia was common and strongly linked with postop-
erative mortality, even after adjustment for major con-
founders [49].
All of the patients with FP included in the analyses 
reported here underwent laparotomy (the diagnosis of 
FP was based on the intra-operative finding of faecal 
soiling of the peritoneal cavity). In addition, a significant 
proportion of patients (40%) were documented to have 
cardiovascular co-morbidity, a group in which anae-
mia has been shown to be associated with worse sur-
vival and major adverse cardiovascular events. Although 
anaemia may be associated with a poor outcome, data 
on the effects of blood transfusion are conflicting, with 
most reports not demonstrating benefit from transfusion 
aimed at achieving a higher haemoglobin threshold [50, 
51].
Limitations
One limitation of the current study is that we were una-
ble to test the performance of other scoring systems such 
as the colorectal POSSUM, the MPI, PIA II or the PSS in 
our dataset, as these systems all require some intra-oper-
ative or preoperative findings, which were not available 
to us. On the other hand, the fact that our scores do not 
require any intra-operative findings could be viewed as 
an advantage.
A further limitation is the lack of comparison with 
alternative and more recent versions of severity scores, 
such as the Simplified Acute Physiology Score (SAPS) 
3, the APACHE III or IV or the Mortality Prediction 
Model (MPM) III. We consider this unlikely to have a 
significant impact on the validity of our results, as mul-
tiple studies have shown that the performance of such 
tools, even in their more recent versions, is not signifi-
cantly improved [52]. A pragmatic decision was made to 
rely on the APACHE II (rather than more recent versions 
of APACHE) in view of its practicality, the fact that it is 
the only available non-proprietary version in widespread 
clinical use [1, 2, 4] and the comparator of choice in mul-
tiple other recently published studies [53, 54].
The SOFA score may be a less than ideal comparator, 
as the SOFA was not originally developed for prognosti-
cation. Multiple previous studies have, however, reported 
using the SOFA score, both in isolation [31–35] and in 
combination with other parameters [36, 37], for outcome 
prediction.
Another limitation is that our study was not designed 
to evaluate the influence on outcome of the timing and 
adequacy of source control or antibiotic treatment. All 
patients included in the study reported here received 
source control via surgical laparotomy prior to recruit-
ment and the overwhelming majority of the patients 
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(91.8%) received antimicrobial therapy deemed to be ade-
quate [24].
Although the homogeneity of the patient population 
within our cohorts represents a methodological strength 
of the study, it may also be considered a potential weak-
ness, as some real-world critically ill patients with FP 
would have not been included in our analyses.
Mortality differed markedly between the cohorts, even 
though they were recruited using the same inclusion 
and exclusion criteria. Whilst it is impossible to identify 
with certainty which factors explain these differences, 
multiple potential reasons can be postulated. Firstly, the 
variation in mortality rates strongly correlates with the 
occurrence of acute renal failure on day one. Acute renal 
dysfunction and deteriorating renal function have both 
been consistently associated with poor outcome in this 
specific subset of patients [24, 25]. The effects of random 
variability and the fact that in the UK the centres recruit-
ing to GenOSept and those recruiting to GAinS were 
not always the same may have also contributed. Finally, 
improvements in the management of sepsis over the 
years may have influenced the incidence of renal failure 
and outcomes.
Conclusions
The present study describes the development of two 
prognostic models for the risk of 6-month and 28-day 
mortality in critically ill septic patients with FP, following 
laparotomy for source control. The tools incorporate five 
of the major independent risk factors identified in previ-
ous studies (SOFA score, age, heart rate, temperature and 
haematocrit) and combine them to produce a numeri-
cal value associated with mortality risk over 6  months 
or 28 days. Although, in the setting of postoperative FP 
patients admitted to critical care, the tools appeared to 
be superior to other existing scoring systems, such as 
SOFA and APACHE II, these findings should not be con-
sidered definitive. External validation in larger cohorts, 
such as the NELA (National Emergency Laparotomy 
Audit) or other databases [55], of their predictive capabil-
ity is needed before introduction of the scores into clini-
cal practice to inform decision making and the design of 
clinical trials.
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